康乐卫士(833575) - 2024 Q4 - 年度业绩预告

Financial Performance - The company expects a net loss attributable to shareholders of between 31,610.72 and 38,635.33 million yuan for the year 2024, representing a change of -28.40% to -5.05% compared to the previous year's loss of 30,090.86 million yuan[5]. - The company has not yet launched any vaccine products for sale since its establishment and has not achieved profitability as of December 31, 2024[7]. - The financial data presented is preliminary and has not been audited by an accounting firm, with the final figures to be disclosed in the 2024 annual report[2][8].